sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Name:
    SARS CoV 2 2019 nCoV Spike RBD His Recombinant Protein COVID 19 Spike RBD Research
    Description:
    A DNA sequence encoding the SARS CoV 2 2019 nCoV Spike Protein RBD YP 009724390 1 Arg319 Phe541 was expressed with a polyhistidine tag at the C terminus
    Catalog Number:
    40592-v08b
    Price:
    None
    Category:
    recombinant protein
    Product Aliases:
    coronavirus spike Protein 2019-nCoV, cov spike Protein 2019-nCoV, ncov RBD Protein 2019-nCoV, ncov s1 Protein 2019-nCoV, ncov s2 Protein 2019-nCoV, ncov spike Protein 2019-nCoV, NCP-CoV RBD Protein 2019-nCoV, NCP-CoV s1 Protein 2019-nCoV, NCP-CoV s2 Protein 2019-nCoV, NCP-CoV Spike Protein 2019-nCoV, novel coronavirus RBD Protein 2019-nCoV, novel coronavirus s1 Protein 2019-nCoV, novel coronavirus s2 Protein 2019-nCoV, novel coronavirus spike Protein 2019-nCoV, RBD Protein 2019-nCoV, S1 Protein 2019-nCoV, S2 Protein 2019-nCoV, Spike RBD Protein 2019-nCoV
    Host:
    Baculovirus-Insect Cells
    Buy from Supplier


    Structured Review

    Sino Biological sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research
    Neutralizing antibody responses to <t>SARS-CoV-2</t> in COVID-19 recovered patients. a Scores showing the COVID-19 patient serum-mediated inhibition of the SARS-CoV-2 RBD protein binding to ACE2 protein by ELISA. b Pie charts showing the proportions of patients with high ( > 50, green) or low (
    A DNA sequence encoding the SARS CoV 2 2019 nCoV Spike Protein RBD YP 009724390 1 Arg319 Phe541 was expressed with a polyhistidine tag at the C terminus
    https://www.bioz.com/result/sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research/product/Sino Biological
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research - by Bioz Stars, 2021-02
    95/100 stars

    Images

    1) Product Images from "Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19"

    Article Title: Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

    Journal: Signal Transduction and Targeted Therapy

    doi: 10.1038/s41392-020-00301-9

    Neutralizing antibody responses to SARS-CoV-2 in COVID-19 recovered patients. a Scores showing the COVID-19 patient serum-mediated inhibition of the SARS-CoV-2 RBD protein binding to ACE2 protein by ELISA. b Pie charts showing the proportions of patients with high ( > 50, green) or low (
    Figure Legend Snippet: Neutralizing antibody responses to SARS-CoV-2 in COVID-19 recovered patients. a Scores showing the COVID-19 patient serum-mediated inhibition of the SARS-CoV-2 RBD protein binding to ACE2 protein by ELISA. b Pie charts showing the proportions of patients with high ( > 50, green) or low (

    Techniques Used: Inhibition, Protein Binding, Enzyme-linked Immunosorbent Assay

    Subtypes of neutralizing antibodies to SARS-CoV-2 S proteins in COVID-19 recovered patients. a Blocking of luciferase-encoding SARS-CoV-2 typed pseudovirus into ACE2/293T cells by patient sera (no depletion) or S1 antibody-depleted sera (S1-Abs depletion) or S2 antibody-depleted sera (S2-Abs depletion). The dashed line indicates the cutoff value (6.749) determined by the ROC curve analysis. HC healthy control, NC negative control. b , c Pie charts showing the proportions of patients with different neutralizing antibody (NAb) subtype responses in the total 25 patients ( b ), 8 severe patients ( c , left panel), and 17 moderate and mild patients ( c , right panel) of pseudovirus neutralization positive. d Blocking of luciferase-encoding SARS-CoV-2 typed pseudovirus into ACE2/293T cells by “S1-NAbs only” patient sera with RBD antibody depletion (RBD-Abs depletion) or without RBD antibody depletion (no depletion). The dashed line indicates the cutoff value (6.034) determined by the ROC curve analysis. HC healthy control, NC negative control. e Pie chart showing the proportions of “S1-NAbs only” patients with RBD-Nab-dependent or -independent antibody response. Error bars in a , d indicate SEM
    Figure Legend Snippet: Subtypes of neutralizing antibodies to SARS-CoV-2 S proteins in COVID-19 recovered patients. a Blocking of luciferase-encoding SARS-CoV-2 typed pseudovirus into ACE2/293T cells by patient sera (no depletion) or S1 antibody-depleted sera (S1-Abs depletion) or S2 antibody-depleted sera (S2-Abs depletion). The dashed line indicates the cutoff value (6.749) determined by the ROC curve analysis. HC healthy control, NC negative control. b , c Pie charts showing the proportions of patients with different neutralizing antibody (NAb) subtype responses in the total 25 patients ( b ), 8 severe patients ( c , left panel), and 17 moderate and mild patients ( c , right panel) of pseudovirus neutralization positive. d Blocking of luciferase-encoding SARS-CoV-2 typed pseudovirus into ACE2/293T cells by “S1-NAbs only” patient sera with RBD antibody depletion (RBD-Abs depletion) or without RBD antibody depletion (no depletion). The dashed line indicates the cutoff value (6.034) determined by the ROC curve analysis. HC healthy control, NC negative control. e Pie chart showing the proportions of “S1-NAbs only” patients with RBD-Nab-dependent or -independent antibody response. Error bars in a , d indicate SEM

    Techniques Used: Blocking Assay, Luciferase, Negative Control, Neutralization

    Antibody responses to SARS-CoV-2 in COVID-19 recovered patients with different symptom severity. a – c ELISA binding assays of 100-fold diluted COVID-19 patient sera to ELISA plates after coating with SARS-CoV-2 S1 ( a ), RBD ( b ), and S2 ( c ) proteins. The dashed lines in a – c represent the average values of the healthy control groups. * P
    Figure Legend Snippet: Antibody responses to SARS-CoV-2 in COVID-19 recovered patients with different symptom severity. a – c ELISA binding assays of 100-fold diluted COVID-19 patient sera to ELISA plates after coating with SARS-CoV-2 S1 ( a ), RBD ( b ), and S2 ( c ) proteins. The dashed lines in a – c represent the average values of the healthy control groups. * P

    Techniques Used: Enzyme-linked Immunosorbent Assay, Binding Assay

    2) Product Images from "Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19"

    Article Title: Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

    Journal: Signal Transduction and Targeted Therapy

    doi: 10.1038/s41392-020-00301-9

    Neutralizing antibody responses to SARS-CoV-2 in COVID-19 recovered patients. a Scores showing the COVID-19 patient serum-mediated inhibition of the SARS-CoV-2 RBD protein binding to ACE2 protein by ELISA. b Pie charts showing the proportions of patients with high ( > 50, green) or low (
    Figure Legend Snippet: Neutralizing antibody responses to SARS-CoV-2 in COVID-19 recovered patients. a Scores showing the COVID-19 patient serum-mediated inhibition of the SARS-CoV-2 RBD protein binding to ACE2 protein by ELISA. b Pie charts showing the proportions of patients with high ( > 50, green) or low (

    Techniques Used: Inhibition, Protein Binding, Enzyme-linked Immunosorbent Assay

    Subtypes of neutralizing antibodies to SARS-CoV-2 S proteins in COVID-19 recovered patients. a Blocking of luciferase-encoding SARS-CoV-2 typed pseudovirus into ACE2/293T cells by patient sera (no depletion) or S1 antibody-depleted sera (S1-Abs depletion) or S2 antibody-depleted sera (S2-Abs depletion). The dashed line indicates the cutoff value (6.749) determined by the ROC curve analysis. HC healthy control, NC negative control. b , c Pie charts showing the proportions of patients with different neutralizing antibody (NAb) subtype responses in the total 25 patients ( b ), 8 severe patients ( c , left panel), and 17 moderate and mild patients ( c , right panel) of pseudovirus neutralization positive. d Blocking of luciferase-encoding SARS-CoV-2 typed pseudovirus into ACE2/293T cells by “S1-NAbs only” patient sera with RBD antibody depletion (RBD-Abs depletion) or without RBD antibody depletion (no depletion). The dashed line indicates the cutoff value (6.034) determined by the ROC curve analysis. HC healthy control, NC negative control. e Pie chart showing the proportions of “S1-NAbs only” patients with RBD-Nab-dependent or -independent antibody response. Error bars in a , d indicate SEM
    Figure Legend Snippet: Subtypes of neutralizing antibodies to SARS-CoV-2 S proteins in COVID-19 recovered patients. a Blocking of luciferase-encoding SARS-CoV-2 typed pseudovirus into ACE2/293T cells by patient sera (no depletion) or S1 antibody-depleted sera (S1-Abs depletion) or S2 antibody-depleted sera (S2-Abs depletion). The dashed line indicates the cutoff value (6.749) determined by the ROC curve analysis. HC healthy control, NC negative control. b , c Pie charts showing the proportions of patients with different neutralizing antibody (NAb) subtype responses in the total 25 patients ( b ), 8 severe patients ( c , left panel), and 17 moderate and mild patients ( c , right panel) of pseudovirus neutralization positive. d Blocking of luciferase-encoding SARS-CoV-2 typed pseudovirus into ACE2/293T cells by “S1-NAbs only” patient sera with RBD antibody depletion (RBD-Abs depletion) or without RBD antibody depletion (no depletion). The dashed line indicates the cutoff value (6.034) determined by the ROC curve analysis. HC healthy control, NC negative control. e Pie chart showing the proportions of “S1-NAbs only” patients with RBD-Nab-dependent or -independent antibody response. Error bars in a , d indicate SEM

    Techniques Used: Blocking Assay, Luciferase, Negative Control, Neutralization

    Antibody responses to SARS-CoV-2 in COVID-19 recovered patients with different symptom severity. a – c ELISA binding assays of 100-fold diluted COVID-19 patient sera to ELISA plates after coating with SARS-CoV-2 S1 ( a ), RBD ( b ), and S2 ( c ) proteins. The dashed lines in a – c represent the average values of the healthy control groups. * P
    Figure Legend Snippet: Antibody responses to SARS-CoV-2 in COVID-19 recovered patients with different symptom severity. a – c ELISA binding assays of 100-fold diluted COVID-19 patient sera to ELISA plates after coating with SARS-CoV-2 S1 ( a ), RBD ( b ), and S2 ( c ) proteins. The dashed lines in a – c represent the average values of the healthy control groups. * P

    Techniques Used: Enzyme-linked Immunosorbent Assay, Binding Assay

    3) Product Images from "SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence"

    Article Title: SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence

    Journal: The Journal of Infectious Diseases

    doi: 10.1093/infdis/jiaa479

    Discrimination of COVID-19 patients with varying severity from a cross-sectional population panel and ILI patients. A , Individuals from the cross-sectional panel aged 3–90 years (n = 224), ILI patients with noncoronavirus (n = 75), and non-SARS-CoV-2 seasonal coronavirus-infected ILI patients (n = 109) were compared to hospitalized and nonhospitalized COVID-19 patients. Median concentration and 95% confidence intervals and statistical results (adjusted P values of Tukey multiple comparison) between the groups are shown. B , Laboratory-confirmed viral infections (see Supplementary Table 2 ) and concentration data of ILI patients are shown to confirm that the assay discriminates SARS-CoV-2–specific antibodies from antibodies induced by various laboratory-confirmed viral infections. Abbreviations: AU, arbitrary unit; COVID-19, coronavirus disease 2019; HCoV, human coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; N, nucleoprotein; non-HCoV, noncoronavirus; RBD, receptor binding domain; RSV, respiratory syncytial virus; S1, spike protein subunit 1.
    Figure Legend Snippet: Discrimination of COVID-19 patients with varying severity from a cross-sectional population panel and ILI patients. A , Individuals from the cross-sectional panel aged 3–90 years (n = 224), ILI patients with noncoronavirus (n = 75), and non-SARS-CoV-2 seasonal coronavirus-infected ILI patients (n = 109) were compared to hospitalized and nonhospitalized COVID-19 patients. Median concentration and 95% confidence intervals and statistical results (adjusted P values of Tukey multiple comparison) between the groups are shown. B , Laboratory-confirmed viral infections (see Supplementary Table 2 ) and concentration data of ILI patients are shown to confirm that the assay discriminates SARS-CoV-2–specific antibodies from antibodies induced by various laboratory-confirmed viral infections. Abbreviations: AU, arbitrary unit; COVID-19, coronavirus disease 2019; HCoV, human coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; N, nucleoprotein; non-HCoV, noncoronavirus; RBD, receptor binding domain; RSV, respiratory syncytial virus; S1, spike protein subunit 1.

    Techniques Used: Infection, Concentration Assay, Binding Assay

    4) Product Images from "A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2)"

    Article Title: A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2)

    Journal: Biosensors & Bioelectronics

    doi: 10.1016/j.bios.2020.112715

    Laboratory confirmation of ACE2-based LFIA using clinical samples a) Schematic diagram of COVID-19 test using ACE2-based LFIA. A nasopharyngeal swab from the COVID-19 patient is placed into the UTM. 50 μL of UTM containing the SARS-CoV-2 is mixed with running buffer in a 1:1 (v/v) ratio, and 100 μL of mixed solution is loaded into the LFIA device. After 20 min, the line intensity of the LFIA strip is semi-quantified by the portable analyzer. b) Results of ACE2-based LFA for the detection sensitivity of cultured SARS-CoV-2. Serially diluted virus concentrates (concentration range: 1.07 × 10 8 copies/mL to 5.35 × 10 6 copies/mL) were tested. After 20 min, the LFIA strip was taken with a smartphone and scanned with an image analyzer. The line intensities of the test and control lines were converted to peak histograms. Also, the intensity of the test lines was measured by a portable line analyzer (I L : line intensity of test line). Furthermore, human coronavirus (OC43) was tested as a negative control. c) Bar graph of intensities for test lines measured by the portable analyzer. The limit of detection (LOD) was determined by the mean value of negative controls (0 copies/mL of SARS-CoV-2) plus three times the standard deviation. d) Laboratory confirmation of ACE2-based LFIA compared to the RT-qPCR using clinical samples. i) Nasopharyngeal swab samples of COVID-19 patients (n = 4) and healthy subjects (n = 4) were tested both ACE2-based LFIA and RT-qPCR. Sensitivity was determined by the number of true positive samples divided by the number of positive samples tested. Moreover, specificity was determined by the number of true negative samples divide by the number of negative samples tested. ii) RT-qPCR results for the detection of the SARS-CoV-2 specific gene (Env gene). C t value and their correspondent viral load in the clinical samples were evaluated. e) Results of ACE2-based LFIA on laboratory confirmation using clinical COVID-19 patient samples. Twenty minutes after sample loading, the test line intensities of the LFIA strips were measured with a portable line analyzer. The limit of detection (LOD) was determined by the mean value of negative controls (healthy control) plus three times the standard deviation.
    Figure Legend Snippet: Laboratory confirmation of ACE2-based LFIA using clinical samples a) Schematic diagram of COVID-19 test using ACE2-based LFIA. A nasopharyngeal swab from the COVID-19 patient is placed into the UTM. 50 μL of UTM containing the SARS-CoV-2 is mixed with running buffer in a 1:1 (v/v) ratio, and 100 μL of mixed solution is loaded into the LFIA device. After 20 min, the line intensity of the LFIA strip is semi-quantified by the portable analyzer. b) Results of ACE2-based LFA for the detection sensitivity of cultured SARS-CoV-2. Serially diluted virus concentrates (concentration range: 1.07 × 10 8 copies/mL to 5.35 × 10 6 copies/mL) were tested. After 20 min, the LFIA strip was taken with a smartphone and scanned with an image analyzer. The line intensities of the test and control lines were converted to peak histograms. Also, the intensity of the test lines was measured by a portable line analyzer (I L : line intensity of test line). Furthermore, human coronavirus (OC43) was tested as a negative control. c) Bar graph of intensities for test lines measured by the portable analyzer. The limit of detection (LOD) was determined by the mean value of negative controls (0 copies/mL of SARS-CoV-2) plus three times the standard deviation. d) Laboratory confirmation of ACE2-based LFIA compared to the RT-qPCR using clinical samples. i) Nasopharyngeal swab samples of COVID-19 patients (n = 4) and healthy subjects (n = 4) were tested both ACE2-based LFIA and RT-qPCR. Sensitivity was determined by the number of true positive samples divided by the number of positive samples tested. Moreover, specificity was determined by the number of true negative samples divide by the number of negative samples tested. ii) RT-qPCR results for the detection of the SARS-CoV-2 specific gene (Env gene). C t value and their correspondent viral load in the clinical samples were evaluated. e) Results of ACE2-based LFIA on laboratory confirmation using clinical COVID-19 patient samples. Twenty minutes after sample loading, the test line intensities of the LFIA strips were measured with a portable line analyzer. The limit of detection (LOD) was determined by the mean value of negative controls (healthy control) plus three times the standard deviation.

    Techniques Used: Stripping Membranes, Cell Culture, Concentration Assay, Negative Control, Standard Deviation, Quantitative RT-PCR

    Related Articles

    Multiplex Assay:

    Article Title: SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalence.
    Article Snippet: Assay ProcedureThe steps in assay validation were similar to recently developed bead-based multiplex immunoassays for CMV, EBV, and RSV, with minor modifications as described below [16, 17]. .. For the multiplex bead-based immune assay the following antigens obtained from Sino Biological were used: SARS-CoV-2 monomeric spike S1 (40591-V08H), RBD (40592-V08B), and nucleoprotein (N) (40588-V08B). ..

    Article Title: SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence
    Article Snippet: Assay Procedure The steps in assay validation were similar to recently developed bead-based multiplex immunoassays for CMV, EBV, and RSV, with minor modifications as described below [ , ]. .. For the multiplex bead-based immune assay the following antigens obtained from Sino Biological were used: SARS-CoV-2 monomeric spike S1 (40591-V08H), RBD (40592-V08B), and nucleoprotein (N) (40588-V08B). ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model
    Article Snippet: Ninety-six well immunosorbent plates (NUNC) were coated with 1ug/mL recombinant SARS-CoV-2 S1+S2 ECD protein (Sino Biological 40589-V08B1), S1 protein (Sino Biological 40591-V08H), S2 protein (Sino Biological 40590-V08B), or receptor-binding domain (RBD) protein (Sino Biological 40595-V05H) in PBS overnight at 4°C. .. ELISA plates were also coated with 1 μg/mL recombinant SARS-CoV S1 protein (Sino Biological 40150-V08B1) and RBD protein (Sino Biological 40592-V08B) or MERS-CoV spike (Sino Biological 40069-V08B). ..

    Article Title: Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
    Article Snippet: .. Enzyme-linked immunosorbent assay As previously described, 50 ng of SARS-CoV-2 S1 protein (Sino Biological, 40591-V08H) or SARS-CoV-2 RBD protein (Sino Biological, 40592-V08B) or SARS-CoV-2 S2 protein (Sino Biological, 40590-V08B) in 100 μl phosphate-buffered saline (PBS) per well was coated on ELISA plates (Costar, 42592) overnight at 4 °C. .. The ELISA plates were blocked for 1 h with 100 μl blocking buffer (5% fetal bovine serum (FBS) and 0.1% Tween 20 in PBS) and then incubated with diluted patient or healthy control sera in 100 μl blocking buffer for 1 h. After washing with PBST buffer (0.1% Tween 20 in PBS), the ELISA plates were incubated with anti-human IgG horseradish peroxidase (HRP) antibody (Bioss Biotech, 0297D) for 45 min, followed by PBST washing and addition of 3,3′,5,5′-tetramethylbenzidine (TMB) buffer (Beyotime, P0209).

    Article Title: Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19
    Article Snippet: .. Reagents Recombinant protein Vendor Catalog SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein Sino Biological 40592-V08H Antibodies Vendor Catalog ELISA Dilution WB Dilution Strep TagII antibody Sigma 71590-3 1:500 1:1000 His Tag antibody Cell Signaling 2365S n/a 1:1000 SARS-CoV-2 (2019-nCoV) Spike RBD Antibody Sino Biological 40592-T62 n/a 1:1000 Goat anti-Human IgG (Fc specific)-Peroxidase Sigma-Aldrich A0170 1:10,000 n/a Goat anti-Mouse IgG (Fc specific)-Peroxidase Sigma-Aldrich A0168 1:10,000 n/a Goat anti-Rabbit IgG (whole molecule)–Peroxidase Sigma-Aldrich A0545 1:5,000 n/a Goat anti-mouse IgG (H) HRP Promega W4021 n/a 1:2000 Donkey anti-rabbit IgG (H) HRP Abcam ab16284 n/a 1:2000 Reagents Vendor Catalog Sodium carbonate (Na2CO3) Fisher Scientific S495-500 Sodium bicarbonate (NaHCO3) Sigma-Aldrich S6014-25G Hydrochoric acid (HCl) Fisher Scientific A144-212 Sodium hydroxide (NaOH) Fisher Scientific S318 Sulfuric acid (H2SO4) Fluka 35276 Tris base Fisher Scientific BP152 Sodium chloride (NaCl) Fisher Scientific BP358-1 Tween 20 Fisher Scientific BP337-500 3,3′,5,5′-Tetramethylbenzidine reagent (TMB) KPL 50-76-06 Bolt™ 4 to 12%, Bis-Tris, 1.0 mm, Mini Protein Gel, 10-well Invitrogen NW04120BOX Bolt™ 10%, Bis-Tris, 1.0 mm, Mini Protein Gel, 12-well Invitrogen NW00102BOX 20X Bolt™ MES SDS Running Buffer Invitrogen B0002 4x Laemmli Sample Buffer Bio-Rad 1610747 Trans-Blot Turbo RTA Mini 0.2 µm PVDF Transfer Kit Bio-Rad 1704272 West-Q Pico ECL Solution GenDEPOT W3652-020 Amersham Hyperfilm ECL cytiva (formerly GE Healthcare) 28906835 SimplyBlue SafeStrain Invitrogen LC6060 EDTA-free protease inhibitor cocktail Roche 04-693-159-001 Precison Plus Protein Dual Color Standards Bio-Rad 161-0374 Protein Purification Reagents Vendor Catalog Qiagen Ni-NTA Superflow 5 mL Qiagen 30761 StrepTrap HP 1 mL cytiva (formerly GE Healthcare) 28907546 Superdex S200 Increase 10/300 GL cytiva (formerly GE Healthcare) 28990944 Amicon® Ultra-4 Centrifugal Filter Unit MilliporeSigma UFC803024 Biotin Sigma-Aldrich B4501. ..

    Recombinant:

    Article Title: Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model
    Article Snippet: Ninety-six well immunosorbent plates (NUNC) were coated with 1ug/mL recombinant SARS-CoV-2 S1+S2 ECD protein (Sino Biological 40589-V08B1), S1 protein (Sino Biological 40591-V08H), S2 protein (Sino Biological 40590-V08B), or receptor-binding domain (RBD) protein (Sino Biological 40595-V05H) in PBS overnight at 4°C. .. ELISA plates were also coated with 1 μg/mL recombinant SARS-CoV S1 protein (Sino Biological 40150-V08B1) and RBD protein (Sino Biological 40592-V08B) or MERS-CoV spike (Sino Biological 40069-V08B). ..

    Article Title: Rapid SARS-CoV-2 Detection Using Electrochemical Immunosensor
    Article Snippet: The spike protein detection antibody (#40591-MM43, Sino Biological) was biotinylated using a 40:1 molar ratio of biotin (#A39259, Thermo Fisher Scientific) to antibody. .. Recombinant Spike subunit 1 protein was applied as a calibrator (#40592-V08B, Sino Biological). .. 22E6 PFU/mL recombinant SARS CoV-2 virus (Linköping University, Linköping, Sweden) was diluted in PBS with 1% BSA, followed by a two-fold dilution in lysis buffer (100 mM Tris-HCl, 800 mM NaCl, pH 9.0, 1% Triton x-100, 1% BSA).

    Article Title: Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19
    Article Snippet: .. Reagents Recombinant protein Vendor Catalog SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein Sino Biological 40592-V08H Antibodies Vendor Catalog ELISA Dilution WB Dilution Strep TagII antibody Sigma 71590-3 1:500 1:1000 His Tag antibody Cell Signaling 2365S n/a 1:1000 SARS-CoV-2 (2019-nCoV) Spike RBD Antibody Sino Biological 40592-T62 n/a 1:1000 Goat anti-Human IgG (Fc specific)-Peroxidase Sigma-Aldrich A0170 1:10,000 n/a Goat anti-Mouse IgG (Fc specific)-Peroxidase Sigma-Aldrich A0168 1:10,000 n/a Goat anti-Rabbit IgG (whole molecule)–Peroxidase Sigma-Aldrich A0545 1:5,000 n/a Goat anti-mouse IgG (H) HRP Promega W4021 n/a 1:2000 Donkey anti-rabbit IgG (H) HRP Abcam ab16284 n/a 1:2000 Reagents Vendor Catalog Sodium carbonate (Na2CO3) Fisher Scientific S495-500 Sodium bicarbonate (NaHCO3) Sigma-Aldrich S6014-25G Hydrochoric acid (HCl) Fisher Scientific A144-212 Sodium hydroxide (NaOH) Fisher Scientific S318 Sulfuric acid (H2SO4) Fluka 35276 Tris base Fisher Scientific BP152 Sodium chloride (NaCl) Fisher Scientific BP358-1 Tween 20 Fisher Scientific BP337-500 3,3′,5,5′-Tetramethylbenzidine reagent (TMB) KPL 50-76-06 Bolt™ 4 to 12%, Bis-Tris, 1.0 mm, Mini Protein Gel, 10-well Invitrogen NW04120BOX Bolt™ 10%, Bis-Tris, 1.0 mm, Mini Protein Gel, 12-well Invitrogen NW00102BOX 20X Bolt™ MES SDS Running Buffer Invitrogen B0002 4x Laemmli Sample Buffer Bio-Rad 1610747 Trans-Blot Turbo RTA Mini 0.2 µm PVDF Transfer Kit Bio-Rad 1704272 West-Q Pico ECL Solution GenDEPOT W3652-020 Amersham Hyperfilm ECL cytiva (formerly GE Healthcare) 28906835 SimplyBlue SafeStrain Invitrogen LC6060 EDTA-free protease inhibitor cocktail Roche 04-693-159-001 Precison Plus Protein Dual Color Standards Bio-Rad 161-0374 Protein Purification Reagents Vendor Catalog Qiagen Ni-NTA Superflow 5 mL Qiagen 30761 StrepTrap HP 1 mL cytiva (formerly GE Healthcare) 28907546 Superdex S200 Increase 10/300 GL cytiva (formerly GE Healthcare) 28990944 Amicon® Ultra-4 Centrifugal Filter Unit MilliporeSigma UFC803024 Biotin Sigma-Aldrich B4501. ..

    Western Blot:

    Article Title: Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19
    Article Snippet: .. Reagents Recombinant protein Vendor Catalog SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein Sino Biological 40592-V08H Antibodies Vendor Catalog ELISA Dilution WB Dilution Strep TagII antibody Sigma 71590-3 1:500 1:1000 His Tag antibody Cell Signaling 2365S n/a 1:1000 SARS-CoV-2 (2019-nCoV) Spike RBD Antibody Sino Biological 40592-T62 n/a 1:1000 Goat anti-Human IgG (Fc specific)-Peroxidase Sigma-Aldrich A0170 1:10,000 n/a Goat anti-Mouse IgG (Fc specific)-Peroxidase Sigma-Aldrich A0168 1:10,000 n/a Goat anti-Rabbit IgG (whole molecule)–Peroxidase Sigma-Aldrich A0545 1:5,000 n/a Goat anti-mouse IgG (H) HRP Promega W4021 n/a 1:2000 Donkey anti-rabbit IgG (H) HRP Abcam ab16284 n/a 1:2000 Reagents Vendor Catalog Sodium carbonate (Na2CO3) Fisher Scientific S495-500 Sodium bicarbonate (NaHCO3) Sigma-Aldrich S6014-25G Hydrochoric acid (HCl) Fisher Scientific A144-212 Sodium hydroxide (NaOH) Fisher Scientific S318 Sulfuric acid (H2SO4) Fluka 35276 Tris base Fisher Scientific BP152 Sodium chloride (NaCl) Fisher Scientific BP358-1 Tween 20 Fisher Scientific BP337-500 3,3′,5,5′-Tetramethylbenzidine reagent (TMB) KPL 50-76-06 Bolt™ 4 to 12%, Bis-Tris, 1.0 mm, Mini Protein Gel, 10-well Invitrogen NW04120BOX Bolt™ 10%, Bis-Tris, 1.0 mm, Mini Protein Gel, 12-well Invitrogen NW00102BOX 20X Bolt™ MES SDS Running Buffer Invitrogen B0002 4x Laemmli Sample Buffer Bio-Rad 1610747 Trans-Blot Turbo RTA Mini 0.2 µm PVDF Transfer Kit Bio-Rad 1704272 West-Q Pico ECL Solution GenDEPOT W3652-020 Amersham Hyperfilm ECL cytiva (formerly GE Healthcare) 28906835 SimplyBlue SafeStrain Invitrogen LC6060 EDTA-free protease inhibitor cocktail Roche 04-693-159-001 Precison Plus Protein Dual Color Standards Bio-Rad 161-0374 Protein Purification Reagents Vendor Catalog Qiagen Ni-NTA Superflow 5 mL Qiagen 30761 StrepTrap HP 1 mL cytiva (formerly GE Healthcare) 28907546 Superdex S200 Increase 10/300 GL cytiva (formerly GE Healthcare) 28990944 Amicon® Ultra-4 Centrifugal Filter Unit MilliporeSigma UFC803024 Biotin Sigma-Aldrich B4501. ..

    Protease Inhibitor:

    Article Title: Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19
    Article Snippet: .. Reagents Recombinant protein Vendor Catalog SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein Sino Biological 40592-V08H Antibodies Vendor Catalog ELISA Dilution WB Dilution Strep TagII antibody Sigma 71590-3 1:500 1:1000 His Tag antibody Cell Signaling 2365S n/a 1:1000 SARS-CoV-2 (2019-nCoV) Spike RBD Antibody Sino Biological 40592-T62 n/a 1:1000 Goat anti-Human IgG (Fc specific)-Peroxidase Sigma-Aldrich A0170 1:10,000 n/a Goat anti-Mouse IgG (Fc specific)-Peroxidase Sigma-Aldrich A0168 1:10,000 n/a Goat anti-Rabbit IgG (whole molecule)–Peroxidase Sigma-Aldrich A0545 1:5,000 n/a Goat anti-mouse IgG (H) HRP Promega W4021 n/a 1:2000 Donkey anti-rabbit IgG (H) HRP Abcam ab16284 n/a 1:2000 Reagents Vendor Catalog Sodium carbonate (Na2CO3) Fisher Scientific S495-500 Sodium bicarbonate (NaHCO3) Sigma-Aldrich S6014-25G Hydrochoric acid (HCl) Fisher Scientific A144-212 Sodium hydroxide (NaOH) Fisher Scientific S318 Sulfuric acid (H2SO4) Fluka 35276 Tris base Fisher Scientific BP152 Sodium chloride (NaCl) Fisher Scientific BP358-1 Tween 20 Fisher Scientific BP337-500 3,3′,5,5′-Tetramethylbenzidine reagent (TMB) KPL 50-76-06 Bolt™ 4 to 12%, Bis-Tris, 1.0 mm, Mini Protein Gel, 10-well Invitrogen NW04120BOX Bolt™ 10%, Bis-Tris, 1.0 mm, Mini Protein Gel, 12-well Invitrogen NW00102BOX 20X Bolt™ MES SDS Running Buffer Invitrogen B0002 4x Laemmli Sample Buffer Bio-Rad 1610747 Trans-Blot Turbo RTA Mini 0.2 µm PVDF Transfer Kit Bio-Rad 1704272 West-Q Pico ECL Solution GenDEPOT W3652-020 Amersham Hyperfilm ECL cytiva (formerly GE Healthcare) 28906835 SimplyBlue SafeStrain Invitrogen LC6060 EDTA-free protease inhibitor cocktail Roche 04-693-159-001 Precison Plus Protein Dual Color Standards Bio-Rad 161-0374 Protein Purification Reagents Vendor Catalog Qiagen Ni-NTA Superflow 5 mL Qiagen 30761 StrepTrap HP 1 mL cytiva (formerly GE Healthcare) 28907546 Superdex S200 Increase 10/300 GL cytiva (formerly GE Healthcare) 28990944 Amicon® Ultra-4 Centrifugal Filter Unit MilliporeSigma UFC803024 Biotin Sigma-Aldrich B4501. ..

    Protein Purification:

    Article Title: Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19
    Article Snippet: .. Reagents Recombinant protein Vendor Catalog SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein Sino Biological 40592-V08H Antibodies Vendor Catalog ELISA Dilution WB Dilution Strep TagII antibody Sigma 71590-3 1:500 1:1000 His Tag antibody Cell Signaling 2365S n/a 1:1000 SARS-CoV-2 (2019-nCoV) Spike RBD Antibody Sino Biological 40592-T62 n/a 1:1000 Goat anti-Human IgG (Fc specific)-Peroxidase Sigma-Aldrich A0170 1:10,000 n/a Goat anti-Mouse IgG (Fc specific)-Peroxidase Sigma-Aldrich A0168 1:10,000 n/a Goat anti-Rabbit IgG (whole molecule)–Peroxidase Sigma-Aldrich A0545 1:5,000 n/a Goat anti-mouse IgG (H) HRP Promega W4021 n/a 1:2000 Donkey anti-rabbit IgG (H) HRP Abcam ab16284 n/a 1:2000 Reagents Vendor Catalog Sodium carbonate (Na2CO3) Fisher Scientific S495-500 Sodium bicarbonate (NaHCO3) Sigma-Aldrich S6014-25G Hydrochoric acid (HCl) Fisher Scientific A144-212 Sodium hydroxide (NaOH) Fisher Scientific S318 Sulfuric acid (H2SO4) Fluka 35276 Tris base Fisher Scientific BP152 Sodium chloride (NaCl) Fisher Scientific BP358-1 Tween 20 Fisher Scientific BP337-500 3,3′,5,5′-Tetramethylbenzidine reagent (TMB) KPL 50-76-06 Bolt™ 4 to 12%, Bis-Tris, 1.0 mm, Mini Protein Gel, 10-well Invitrogen NW04120BOX Bolt™ 10%, Bis-Tris, 1.0 mm, Mini Protein Gel, 12-well Invitrogen NW00102BOX 20X Bolt™ MES SDS Running Buffer Invitrogen B0002 4x Laemmli Sample Buffer Bio-Rad 1610747 Trans-Blot Turbo RTA Mini 0.2 µm PVDF Transfer Kit Bio-Rad 1704272 West-Q Pico ECL Solution GenDEPOT W3652-020 Amersham Hyperfilm ECL cytiva (formerly GE Healthcare) 28906835 SimplyBlue SafeStrain Invitrogen LC6060 EDTA-free protease inhibitor cocktail Roche 04-693-159-001 Precison Plus Protein Dual Color Standards Bio-Rad 161-0374 Protein Purification Reagents Vendor Catalog Qiagen Ni-NTA Superflow 5 mL Qiagen 30761 StrepTrap HP 1 mL cytiva (formerly GE Healthcare) 28907546 Superdex S200 Increase 10/300 GL cytiva (formerly GE Healthcare) 28990944 Amicon® Ultra-4 Centrifugal Filter Unit MilliporeSigma UFC803024 Biotin Sigma-Aldrich B4501. ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Sino Biological sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research
    Laboratory confirmation of ACE2-based LFIA using clinical samples a) Schematic diagram of <t>COVID-19</t> test using ACE2-based LFIA. A nasopharyngeal swab from the COVID-19 patient is placed into the UTM. 50 μL of UTM containing the <t>SARS-CoV-2</t> is mixed with running buffer in a 1:1 (v/v) ratio, and 100 μL of mixed solution is loaded into the LFIA device. After 20 min, the line intensity of the LFIA strip is semi-quantified by the portable analyzer. b) Results of ACE2-based LFA for the detection sensitivity of cultured SARS-CoV-2. Serially diluted virus concentrates (concentration range: 1.07 × 10 8 copies/mL to 5.35 × 10 6 copies/mL) were tested. After 20 min, the LFIA strip was taken with a smartphone and scanned with an image analyzer. The line intensities of the test and control lines were converted to peak histograms. Also, the intensity of the test lines was measured by a portable line analyzer (I L : line intensity of test line). Furthermore, human coronavirus (OC43) was tested as a negative control. c) Bar graph of intensities for test lines measured by the portable analyzer. The limit of detection (LOD) was determined by the mean value of negative controls (0 copies/mL of SARS-CoV-2) plus three times the standard deviation. d) Laboratory confirmation of ACE2-based LFIA compared to the RT-qPCR using clinical samples. i) Nasopharyngeal swab samples of COVID-19 patients (n = 4) and healthy subjects (n = 4) were tested both ACE2-based LFIA and RT-qPCR. Sensitivity was determined by the number of true positive samples divided by the number of positive samples tested. Moreover, specificity was determined by the number of true negative samples divide by the number of negative samples tested. ii) RT-qPCR results for the detection of the SARS-CoV-2 specific gene (Env gene). C t value and their correspondent viral load in the clinical samples were evaluated. e) Results of ACE2-based LFIA on laboratory confirmation using clinical COVID-19 patient samples. Twenty minutes after sample loading, the test line intensities of the LFIA strips were measured with a portable line analyzer. The limit of detection (LOD) was determined by the mean value of negative controls (healthy control) plus three times the standard deviation.
    Sars Cov 2 2019 Ncov Spike Rbd His Recombinant Protein Covid 19 Spike Rbd Research, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research/product/Sino Biological
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research - by Bioz Stars, 2021-02
    95/100 stars
      Buy from Supplier

    Image Search Results


    Laboratory confirmation of ACE2-based LFIA using clinical samples a) Schematic diagram of COVID-19 test using ACE2-based LFIA. A nasopharyngeal swab from the COVID-19 patient is placed into the UTM. 50 μL of UTM containing the SARS-CoV-2 is mixed with running buffer in a 1:1 (v/v) ratio, and 100 μL of mixed solution is loaded into the LFIA device. After 20 min, the line intensity of the LFIA strip is semi-quantified by the portable analyzer. b) Results of ACE2-based LFA for the detection sensitivity of cultured SARS-CoV-2. Serially diluted virus concentrates (concentration range: 1.07 × 10 8 copies/mL to 5.35 × 10 6 copies/mL) were tested. After 20 min, the LFIA strip was taken with a smartphone and scanned with an image analyzer. The line intensities of the test and control lines were converted to peak histograms. Also, the intensity of the test lines was measured by a portable line analyzer (I L : line intensity of test line). Furthermore, human coronavirus (OC43) was tested as a negative control. c) Bar graph of intensities for test lines measured by the portable analyzer. The limit of detection (LOD) was determined by the mean value of negative controls (0 copies/mL of SARS-CoV-2) plus three times the standard deviation. d) Laboratory confirmation of ACE2-based LFIA compared to the RT-qPCR using clinical samples. i) Nasopharyngeal swab samples of COVID-19 patients (n = 4) and healthy subjects (n = 4) were tested both ACE2-based LFIA and RT-qPCR. Sensitivity was determined by the number of true positive samples divided by the number of positive samples tested. Moreover, specificity was determined by the number of true negative samples divide by the number of negative samples tested. ii) RT-qPCR results for the detection of the SARS-CoV-2 specific gene (Env gene). C t value and their correspondent viral load in the clinical samples were evaluated. e) Results of ACE2-based LFIA on laboratory confirmation using clinical COVID-19 patient samples. Twenty minutes after sample loading, the test line intensities of the LFIA strips were measured with a portable line analyzer. The limit of detection (LOD) was determined by the mean value of negative controls (healthy control) plus three times the standard deviation.

    Journal: Biosensors & Bioelectronics

    Article Title: A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2)

    doi: 10.1016/j.bios.2020.112715

    Figure Lengend Snippet: Laboratory confirmation of ACE2-based LFIA using clinical samples a) Schematic diagram of COVID-19 test using ACE2-based LFIA. A nasopharyngeal swab from the COVID-19 patient is placed into the UTM. 50 μL of UTM containing the SARS-CoV-2 is mixed with running buffer in a 1:1 (v/v) ratio, and 100 μL of mixed solution is loaded into the LFIA device. After 20 min, the line intensity of the LFIA strip is semi-quantified by the portable analyzer. b) Results of ACE2-based LFA for the detection sensitivity of cultured SARS-CoV-2. Serially diluted virus concentrates (concentration range: 1.07 × 10 8 copies/mL to 5.35 × 10 6 copies/mL) were tested. After 20 min, the LFIA strip was taken with a smartphone and scanned with an image analyzer. The line intensities of the test and control lines were converted to peak histograms. Also, the intensity of the test lines was measured by a portable line analyzer (I L : line intensity of test line). Furthermore, human coronavirus (OC43) was tested as a negative control. c) Bar graph of intensities for test lines measured by the portable analyzer. The limit of detection (LOD) was determined by the mean value of negative controls (0 copies/mL of SARS-CoV-2) plus three times the standard deviation. d) Laboratory confirmation of ACE2-based LFIA compared to the RT-qPCR using clinical samples. i) Nasopharyngeal swab samples of COVID-19 patients (n = 4) and healthy subjects (n = 4) were tested both ACE2-based LFIA and RT-qPCR. Sensitivity was determined by the number of true positive samples divided by the number of positive samples tested. Moreover, specificity was determined by the number of true negative samples divide by the number of negative samples tested. ii) RT-qPCR results for the detection of the SARS-CoV-2 specific gene (Env gene). C t value and their correspondent viral load in the clinical samples were evaluated. e) Results of ACE2-based LFIA on laboratory confirmation using clinical COVID-19 patient samples. Twenty minutes after sample loading, the test line intensities of the LFIA strips were measured with a portable line analyzer. The limit of detection (LOD) was determined by the mean value of negative controls (healthy control) plus three times the standard deviation.

    Article Snippet: 2.2 Biolayer interferometryFc-tag tagged human ACE2 (ACE2, Cat. No. 10108-H05H), SARS-CoV-2 spike monoclonal antibody (S1-mAb, Cat. No. 40150-R007), SARS-CoV-2 spike protein (S1 subunit, Cat. No. 40591-V08H), and SARS-CoV-2 RBD (Cat. No. 40592-V08B) were purchased from Sino Biological.

    Techniques: Stripping Membranes, Cell Culture, Concentration Assay, Negative Control, Standard Deviation, Quantitative RT-PCR

    Neutralizing antibody responses to SARS-CoV-2 in COVID-19 recovered patients. a Scores showing the COVID-19 patient serum-mediated inhibition of the SARS-CoV-2 RBD protein binding to ACE2 protein by ELISA. b Pie charts showing the proportions of patients with high ( > 50, green) or low (

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

    doi: 10.1038/s41392-020-00301-9

    Figure Lengend Snippet: Neutralizing antibody responses to SARS-CoV-2 in COVID-19 recovered patients. a Scores showing the COVID-19 patient serum-mediated inhibition of the SARS-CoV-2 RBD protein binding to ACE2 protein by ELISA. b Pie charts showing the proportions of patients with high ( > 50, green) or low (

    Article Snippet: Depletion of SARS-CoV-2 S protein-specific antibodiesFirst, SARS-CoV-2 S1 protein (Sino Biological, 40591-V08H) or SARS-CoV-2 RBD protein (Sino Biological, 40592-V08B) or SARS-CoV-2 S2 protein was conjugated with biotin by following the manufacturer’s protocol (Thermo Fisher Scientific, A39257).

    Techniques: Inhibition, Protein Binding, Enzyme-linked Immunosorbent Assay

    Subtypes of neutralizing antibodies to SARS-CoV-2 S proteins in COVID-19 recovered patients. a Blocking of luciferase-encoding SARS-CoV-2 typed pseudovirus into ACE2/293T cells by patient sera (no depletion) or S1 antibody-depleted sera (S1-Abs depletion) or S2 antibody-depleted sera (S2-Abs depletion). The dashed line indicates the cutoff value (6.749) determined by the ROC curve analysis. HC healthy control, NC negative control. b , c Pie charts showing the proportions of patients with different neutralizing antibody (NAb) subtype responses in the total 25 patients ( b ), 8 severe patients ( c , left panel), and 17 moderate and mild patients ( c , right panel) of pseudovirus neutralization positive. d Blocking of luciferase-encoding SARS-CoV-2 typed pseudovirus into ACE2/293T cells by “S1-NAbs only” patient sera with RBD antibody depletion (RBD-Abs depletion) or without RBD antibody depletion (no depletion). The dashed line indicates the cutoff value (6.034) determined by the ROC curve analysis. HC healthy control, NC negative control. e Pie chart showing the proportions of “S1-NAbs only” patients with RBD-Nab-dependent or -independent antibody response. Error bars in a , d indicate SEM

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

    doi: 10.1038/s41392-020-00301-9

    Figure Lengend Snippet: Subtypes of neutralizing antibodies to SARS-CoV-2 S proteins in COVID-19 recovered patients. a Blocking of luciferase-encoding SARS-CoV-2 typed pseudovirus into ACE2/293T cells by patient sera (no depletion) or S1 antibody-depleted sera (S1-Abs depletion) or S2 antibody-depleted sera (S2-Abs depletion). The dashed line indicates the cutoff value (6.749) determined by the ROC curve analysis. HC healthy control, NC negative control. b , c Pie charts showing the proportions of patients with different neutralizing antibody (NAb) subtype responses in the total 25 patients ( b ), 8 severe patients ( c , left panel), and 17 moderate and mild patients ( c , right panel) of pseudovirus neutralization positive. d Blocking of luciferase-encoding SARS-CoV-2 typed pseudovirus into ACE2/293T cells by “S1-NAbs only” patient sera with RBD antibody depletion (RBD-Abs depletion) or without RBD antibody depletion (no depletion). The dashed line indicates the cutoff value (6.034) determined by the ROC curve analysis. HC healthy control, NC negative control. e Pie chart showing the proportions of “S1-NAbs only” patients with RBD-Nab-dependent or -independent antibody response. Error bars in a , d indicate SEM

    Article Snippet: Depletion of SARS-CoV-2 S protein-specific antibodiesFirst, SARS-CoV-2 S1 protein (Sino Biological, 40591-V08H) or SARS-CoV-2 RBD protein (Sino Biological, 40592-V08B) or SARS-CoV-2 S2 protein was conjugated with biotin by following the manufacturer’s protocol (Thermo Fisher Scientific, A39257).

    Techniques: Blocking Assay, Luciferase, Negative Control, Neutralization

    Antibody responses to SARS-CoV-2 in COVID-19 recovered patients with different symptom severity. a – c ELISA binding assays of 100-fold diluted COVID-19 patient sera to ELISA plates after coating with SARS-CoV-2 S1 ( a ), RBD ( b ), and S2 ( c ) proteins. The dashed lines in a – c represent the average values of the healthy control groups. * P

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

    doi: 10.1038/s41392-020-00301-9

    Figure Lengend Snippet: Antibody responses to SARS-CoV-2 in COVID-19 recovered patients with different symptom severity. a – c ELISA binding assays of 100-fold diluted COVID-19 patient sera to ELISA plates after coating with SARS-CoV-2 S1 ( a ), RBD ( b ), and S2 ( c ) proteins. The dashed lines in a – c represent the average values of the healthy control groups. * P

    Article Snippet: Depletion of SARS-CoV-2 S protein-specific antibodiesFirst, SARS-CoV-2 S1 protein (Sino Biological, 40591-V08H) or SARS-CoV-2 RBD protein (Sino Biological, 40592-V08B) or SARS-CoV-2 S2 protein was conjugated with biotin by following the manufacturer’s protocol (Thermo Fisher Scientific, A39257).

    Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay

    Discrimination of COVID-19 patients with varying severity from a cross-sectional population panel and ILI patients. A , Individuals from the cross-sectional panel aged 3–90 years (n = 224), ILI patients with noncoronavirus (n = 75), and non-SARS-CoV-2 seasonal coronavirus-infected ILI patients (n = 109) were compared to hospitalized and nonhospitalized COVID-19 patients. Median concentration and 95% confidence intervals and statistical results (adjusted P values of Tukey multiple comparison) between the groups are shown. B , Laboratory-confirmed viral infections (see Supplementary Table 2 ) and concentration data of ILI patients are shown to confirm that the assay discriminates SARS-CoV-2–specific antibodies from antibodies induced by various laboratory-confirmed viral infections. Abbreviations: AU, arbitrary unit; COVID-19, coronavirus disease 2019; HCoV, human coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; N, nucleoprotein; non-HCoV, noncoronavirus; RBD, receptor binding domain; RSV, respiratory syncytial virus; S1, spike protein subunit 1.

    Journal: The Journal of Infectious Diseases

    Article Title: SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence

    doi: 10.1093/infdis/jiaa479

    Figure Lengend Snippet: Discrimination of COVID-19 patients with varying severity from a cross-sectional population panel and ILI patients. A , Individuals from the cross-sectional panel aged 3–90 years (n = 224), ILI patients with noncoronavirus (n = 75), and non-SARS-CoV-2 seasonal coronavirus-infected ILI patients (n = 109) were compared to hospitalized and nonhospitalized COVID-19 patients. Median concentration and 95% confidence intervals and statistical results (adjusted P values of Tukey multiple comparison) between the groups are shown. B , Laboratory-confirmed viral infections (see Supplementary Table 2 ) and concentration data of ILI patients are shown to confirm that the assay discriminates SARS-CoV-2–specific antibodies from antibodies induced by various laboratory-confirmed viral infections. Abbreviations: AU, arbitrary unit; COVID-19, coronavirus disease 2019; HCoV, human coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; N, nucleoprotein; non-HCoV, noncoronavirus; RBD, receptor binding domain; RSV, respiratory syncytial virus; S1, spike protein subunit 1.

    Article Snippet: For the multiplex bead-based immune assay the following antigens obtained from Sino Biological were used: SARS-CoV-2 monomeric spike S1 (40591-V08H), RBD (40592-V08B), and nucleoprotein (N) (40588-V08B).

    Techniques: Infection, Concentration Assay, Binding Assay